GMVD Nasdaq, page-13

First 13 Last

Share
Profile

Follow
Upthefog

1,672 Posts.

590

10/07/21

17:38

Post #: 54417305
Share

Originally posted by trippster ↑

Really good to see some chatter here again. I’ve stayed pretty free of emotions through this situation. I see that the devices are sophisticated, but the business really uses the devices as a way to provide TELEHEALTH SERVICES. One thing I debate with myself often is which device will bring in more recurring revenues. I feel that Prizma is more targeted to consumers driven by GP’s and Health Insurance companies. And the Patch will be more targeted to Hospitals.

USA is the obvious market they want to go for, alongside China (factory already ready). Huge markets for both countries. I am interested in what people’s thoughts are on which device will be more successful in the short, medium, longer term by way of cloud storage fees, Telehealth consults, monitoring, etc etc. Guthy Renker are great. They market and sell products very well. Great to see them on board too.

Hope the old school posters return. New page, new chapter, new beginning. We have to blow the dust off our boots, give the boots a good polish and shine, and realise it’s Nasdaq time.

Expand

Don’t get me wrong - I want the company to shoot the lights out in terms revenue & profitability. I guess this again raises the question of whether the company is a device seller or a tele-health monitoring company. Similarly - is the device selling via Guthy Renker inconsistent with our service offering to University hospitals. Guthy Renker which a valid distribution network is a tad “low brow” compared with the sophisticated service offering to hospitals. As I said revenue is revenue but can the company hope to succeed at both?

GMV Price at posting: 3.9¢ Sentiment: Hold Disclosure: Held
2 Upvote

2 Great analysis

Reply